Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.
Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma (HCC).
According to Gkika, sorafenib (Nexavar) is no longer the standard of care for advanced HCC. The IMbrave-150 study (NCT03434379) established the immunotherapy combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) as the current standard of care.
However, Gkika says that results for this combination is still not good in terms in overall survival and response rate. Tumor targeting fields have been found to be effective against several types of aggressive cancers. The HEPANOVA study (NCT03606590) aims to determine if this is correct for advanced HCC as well.
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More